🔗 Permalink

Inventor profile of:

Shaoling Li

City:

Sunnyvale, California

Country:

United States

Published Applications:

Last publication date:

2024-11-21

Top Assignees for applications by Shaoling Li

The entities that hold a legal rights for patent applications filed by inventor Li Shaoling:

THERAVANCE BIOPHARMA R&D IP, LLC 4 South San Francisco, CA United States
ALZA Corporation 3 Mountain View, CA United States
NANJING UNIVERSITY 1 Nanjing, China
NanoPax Pharma, LLC 1 Long Grove, IL United States
Nanjing Effect Pharm Drug Development Corporation 1 Nanjing, China

Recent patent applications by Li Shaoling

Shaoling Li from Sunnyvale, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2024-11-21

US20240383920A1

Chemistry; metallurgy

SYNTHESIS OF RAS INHIBITORS

#2 | 2024-11-07

US20240368190A1

Chemistry; metallurgy

SYNTHESIS OF RAS INHIBITORS

#3 | 2024-10-24

US20240352038A1

Chemistry; metallurgy

CRYSTALLINE FORMS OF RAS INHIBITORS, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USE THEREOF

#4 | 2024-10-24

US20240352036A1

Chemistry; metallurgy

CRYSTALLINE FORMS OF RAS INHIBITORS, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USE THEREOF

#5 | 2021-06-03

US20210161884A1

Human necessities

Combination dosage form of a mu opioid receptor antagonist and an opioid agent

#6 | 2021-04-22

US20210113541A1

Human necessities

TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF

#7 | 2020-09-17

US20200289488A1

Human necessities

TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF

#8 | 2020-02-20

US20200054619A1

Human necessities

TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF

#9 | 2019-10-24

US20190321350A1

Human necessities

Combination dosage form of a mu opioid receptor antagonist and an opioid agent

#10 | 2019-06-06

US20190167655A1

Human necessities

Transdermal Administration Of Fentanyl And Analogs Thereof

#11 | 2018-04-12

US20180098979A1

Human necessities

TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF

#12 | 2018-02-22

US20180050028A1

Human necessities

Combination dosage form of a mu opioid receptor antagonist and an opioid agent

#13 | 2016-11-17

US20160331740A1

Human necessities

TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF

#14 | 2016-10-06

US20160287573A1

Human necessities

COMBINATION DOSAGE FORM OF A MU OPIOID RECEPTOR ANTAGONIST AND AN OPIOID AGENT

#15 | 2014-09-18

US20140271799A1

Human necessities

TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF

#16 | 2014-01-30

US20140030316A1

Human necessities

TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF

#17 | 2011-03-10

US20110059181A1

Human necessities

Methods for drug delivery comprising unfolding and folding proteins and peptide nanoparticles

#18 | 2009-06-25

US20090162431A1

Human necessities

Sustained release formulations containing acetaminophen and tramadol

#19 | 2009-01-01

US20090004257A1

Human necessities

TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF

#20 | 2008-03-04

US10609061

Expandable osmotic composition and coating suspension

#21 | 2007-10-18

US20070243254A1

Human necessities

NOVEL DRUG COMPOSITIONS AND DOSAGE FORMS OF TOPIRAMATE

#22 | 2005-09-22

US20050208117A1

Human necessities

Transdermal administration of fentanyl and analogs thereof

#23 | 2005-08-11

US20050175697A1

Human necessities

Novel drug compositions and dosage forms of topiramate

#24 | 2005-08-11

US20050175690A1

Human necessities

Novel drug compositions and dosage forms

#25 | 2005-06-16

US20050129765A1

Human necessities

Controlled release of topiramate in liquid dosage forms

#26 | 2005-03-17

US20050058707A1

Human necessities

Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation

InventorID:

630973 ⎘